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ABSTRACT  
Introduction 
Objective assessment of symptoms in bronchiectasis is important for research and in clinical practice. 
The COPD Assessment Test (CAT) is a short, simple assessment tool widely used in chronic obstructive 
pulmonary disease (COPD). The items included in the CAT are not specific to COPD and also reflect the 
dominant symptoms of bronchiectasis. We therefore performed a study to validate the CAT as an 
outcome measure in bronchiectasis.  
Methods 
The CAT was administered to two cohorts of bronchiectasis patients along with other quality of life 
questionnaires. Patients underwent comprehensive clinical assessment. One cohort had repeated 
questionnaires collected before-and-after treatment of acute exacerbations. We analysed convergent 
validity, repeatability and responsiveness of the score and calculated the minimum clinically important 
difference (MCID) using a combination of distribution and anchor based methods. 
Results 
In both cohorts there were positive correlations between the CAT and the St.George’s Respiratory 
Questionnaire (SGRQ) (r=0.90,p<0.0001 and r=0.87,p<0.0001). There was an inverse relationship 
between CAT and Quality of Life – Bronchiectasis Respiratory Symptoms Scale (QOL-B-RSS) (r=-
0.75,p<0.0001) and Leicester Cough Questionnaire score (r=-0.77,p<0.0001). Patients with more severe 
disease, based on the Bronchiectasis severity index, had significantly higher CAT scores. CAT also 
correlated with FEV1 %predicted and 6-minute walk distance. CAT increased significantly at exacerbation 
and fell at recovery. The intraclass correlation coefficient for two measurements four-weeks apart while 
clinically stable was 0.88 (95%CI 0.73 to 0.95,p<0.0001). An MCID of 4 was most consistent. 
Discussion 
CAT is a valid, responsive symptom assessment tool in bronchiectasis. The MCID is estimated as 4 points.  
 
 
Introduction 
Bronchiectasis is a condition which has a significant long-term impact on quality of life (QOL).
1,2
 Patients 
experience daily cough, sputum, fatigue, chest discomfort, rhinosinusitis and breathlessness along with 
frequent exacerbations in many cases.
3–5
 QOL is also impaired by social, psychological, physical and 
treatment-related factors such as the burden of treatment from daily chest physiotherapy and 
medications including oral and nebulised drugs.
2,3,6–8
  
QoL and symptom assessments are key measureable outcomes in bronchiectasis management. They are 
among the most important clinical trial endpoints and therefore having valid tools to assess quality of 
life is essential for both research and daily clinical practice.2,9,10 Several different tools have been applied 
to studying bronchiectasis including tools originally developed for other respiratory diseases such as the 
St. George’s Respiratory Questionnaire (SGRQ) and those developed specifically for bronchiectasis such 
as the Quality of Life – Bronchiectasis questionnaire (QOL-B).
2,5,9,11
  
The use of specific tools are attractive in order to capture the variety of features that are unique to a 
certain condition and elucidate the individual patient factors which may require specific attention. There 
is, however, a high degree of overlap between chronic obstructive pulmonary disease (COPD), 
bronchiectasis and asthma, with up to 50% of patients with COPD being reported to have bronchiectasis 
and up to 50% of bronchiectasis patients reporting a past history of asthma.
12–14
 Disease labels are 
increasingly being abandoned in favour of a treatable traits concept that acknowledges the 
heterogeneity of airways disease.15–17 The high degree of similarity in the symptoms of the three major 
airways diseases may explain why the SGRQ, despite not being designed for use in bronchiectasis, has 
been shown to be consistently associated with bronchiectasis disease severity measures, and to be 
responsive to treatments including inhaled antibiotics.
11,18–21
 In the RESPIRE programme, treatment with 
inhaled dry powder ciprofloxacin resulted in a significant improvement in the SGRQ in RESPIRE 1 
(adjusted difference -7.59, p=0.009 and -5.21, p=0.06 in the 14-day on/off and 28-day on/off arms, with 
a minimum clinically important difference (MCID) of 4) while the disease specific QOL-B questionnaire 
failed to demonstrate responsiveness (adjusted difference 2.47, p=0.3 and 1.18, p=0.6 with a MCID of 
8).
20
  
There is therefore a strong rationale for considering using validated symptom assessment tools across 
diseases. The COPD Assessment Tool (CAT) is a short, eight-question, patient-administered 
questionnaire that was developed for use in COPD. Score ranges from 0-40, with higher scores indicating 
more severe symptoms. It has been shown to be comparable to the SGRQ in COPD.
22–24
 Symptoms 
covered are cough, sputum production, chest tightness, exertional dyspnoea, activities of daily living, 
confidence, sleep and energy, all of which are also key components of disease specific bronchiectasis 
tools. The simplicity of the CAT as well as its established performance characteristics in COPD makes it 
an attractive potential tool for bronchiectasis patients. The CAT is currently being evaluated in several 
studies as it has been recognised to have validity for other chronic airways diseases and in this context 
has been renamed as the Chronic Airways Assessment Test (CAAT). 
(https://clinicaltrials.gov/ct2/show/NCT02760329)  Pilot studies suggest that the CAT correlates with 
clinically important outcomes in bronchiectasis.
25
  
This study was therefore designed to validate the CAT questionnaire for use in bronchiectasis and to 
determine the minimum clinically important difference. 
 
Methods 
We performed a prospective study designed to evaluate the convergent validity, responsiveness and 
clinical utility of the CAT in patients with bronchiectasis. The study was approved by the local research 
ethics committee (13/ES/0062) and all patients gave written informed consent to participate. 
The CAT was evaluated in two distinct studies, the Tayside rehabilitation in bronchiectasis exacerbations 
(TRIBE) randomized trial, which was a longitudinal evaluation of the CAT, and a cross-sectional validation 
cohort in which the CAT was performed at a single time point. These are referred to as the TRIBE cohort 
and the Validation cohort throughout the manuscript. 
TRIBE cohort 
Details of the TRIBE trial have been previously published.26 Patients were enrolled from 2014-2017. The 
CAT was a secondary endpoint in the TRIBE study and evaluation and validation of the CAT 
questionnaire was a pre-specified substudy. Patients were enrolled in the study if they had high 
resolution CT (HRCT) confirmed bronchiectasis and at least one exacerbation in the previous year. 
Patients were excluded if they were aged <18 years, had a diagnosis of cystic fibrosis (CF) or an 
exacerbation in the previous four weeks. Patients completed the CAT questionnaire at screening as well 
as undergoing a clinical evaluation including lung function and 6 minute walk test (6MWT) according to 
standard guidelines.
26
 Baseline data were used to confirm convergent validity of the CAT in a second 
cohort of patients. Importantly, the TRIBE study specifically excluded patients with any history of COPD 
(defined as a history of at least 10 pack years cigarette smoking and an FEV1/FVC ratio less than 0.7 
along with a clinical diagnosis of COPD). Patients also completed the SGRQ and Leicester Cough 
Questionnaire (LCQ) at each visit. Of note, this study was initiated prior to publication of the QOL-B 
questionnaire and so data on this questionnaire were not available for comparison.  
Patients who met eligibility criteria for the TRIBE study were then asked to contact the site when they 
developed symptoms of an acute exacerbation. Detection of exacerbations was supported by daily 
diaries. Exacerbations were defined as an increase in respiratory symptoms requiring antibiotic 
treatment as determined by a clinician. Patients attending for an exacerbation visit then completed the 
CAT again, followed by a further visit two weeks later after completion of 14 days treatment with 
antibiotics for an acute exacerbation.
26
  
Patients were subsequently randomized to pulmonary rehabilitation or standard care. The CAT was 
repeated at week 8 and week 12 following the exacerbation (after completion of pulmonary 
rehabilitation and at the end of the study respectively).  
Cross-sectional validation cohort 
In this validation analysis, 83 patients were prospectively enrolled from a specialist tertiary referral 
centre in the UK over a 12 month period. None of the included patients overlapped with those included 
in TRIBE. Patients were required to be clinically stable for four weeks prior to enrolment and have 
clinically significant bronchiectasis and confirmation of the diagnosis on an HRCT scan. Patients were 
excluded if they had a primary diagnosis of COPD, asthma, CF or other respiratory condition. Patients 
were evaluated according to British Thoracic Society recommendations including a comprehensive work-
up for potential underlying causes.
27
 The QOL-B and SGRQ were administered alongside the CAT for 
comparison.  This study was cross-sectional with no repeated evaluation of the CAT questionnaire. 
Convergent validity  
This represents an assessment of the instrument against other measures that are considered to 
represent severity of disease, since a valid instrument should agree with clinical assessments of severity 
of disease and disease burden.
9
 The CAT questionnaire was tested for its correlation with other 
validated questionnaires (QOL-B, SGRQ, LCQ). For convergent validity assessment, the CAT was 
correlated with these questionnaires, but also with recognised measures of bronchiectasis severity 
including the BSI, exacerbation frequency, FEV1 and self-reported daily sputum volume.
28
 In the TRIBE 
study, CAT was also correlated with 6 minute walk distance (6MWD). All assessments were performed 
on the same day as administration of the CAT.  
Repeatability 
Patients completed the CAT during two visits one month apart, if they reported stable symptoms, to 
determine the repeatability of the measure. Patients were excluded if they reported a change in 
symptoms or an exacerbation during this one-month period. 
Minimum clinically important difference  
The MCID can be calculated through distribution-based or anchor-based methods and there is no agreed 
optimal method for MCID estimation.
23
 For this study we calculated both distribution-based methods 
using ½ the baseline standard deviation of the measure and an anchor-based method using three 
clinically relevant anchors: the mean change in CAT at the onset of exacerbation (a clinically meaningful 
negative change in patient symptoms), the change from exacerbation to recovery from exacerbation (a 
clinically meaningful change in patients symptoms in the positive direction) and the change during the 
course of the TRIBE study anchored to the SGRQ. It is acknowledged that there is no finalised MCID for 
any quality of life tool in bronchiectasis, apart from a MCID of 4 for the SGRQ that has been extensively 
used in bronchiectasis and so was selected for this study.
11
  
Statistical analysis 
SPSS version 22.0 (SPSS, Chicago, IL, USA), Prism version 6 (GraphPad, La Jolla, CA, USA) were used for 
analysis. We present mean with standard deviation for parametric distributions or median with 
interquartile range for non-parametric distributions as appropriate. Comparisons across more than 2 
groups were performed using ANOVA. Correlations between variables were assessed with linear 
regression, Pearsons r and Spearmans p as appropriate. Repeatability was evaluated using the intraclass 
correlation coefficient and a Bland-Altman plot. P<0.05 was considered statistically significant.  
 
Results 
Cohort description 
TRIBE cohort 
Forty-eight patients were enrolled and they completed a CAT questionnaire at each visit. The mean age 
was 67 years (7.5) and there were 31 females (64.6%). The mean bronchiectasis severity index (BSI) 
score was 6.6 (3.2) and mean FEV1 % predicted was 78.8% (26.6). Baseline CAT score ranged from 4 to 
37. Twenty-four of the 48 patients enrolled had an exacerbation during the 12-month follow period and 
provided additional data at onset and recovery from exacerbation. Characteristics of this patient 
population are shown in table S1 online.  
Cross-sectional validation cohort 
Eighty-three patients were included and 80.7% were classified as idiopathic. The mean age was 71 years 
(9.5) and 45 (54.2%) were female. In keeping with the tertiary referral nature of this population, the 
patients had more severe disease than the TRIBE cohort, with a mean FEV1 % predicted of 52% (13.2). 
The mean exacerbation frequency was 2 per year (IQR 0-3) and 56.6% were classified as severe using the 
BSI (table S2 online). Haemophilus influenzae was the most frequent organism found in 33.7% of the 
cohort with P. aeruginosa found in 18.1%.  
Convergent validity - SGRQ 
Both cohorts completed CAT and SGRQ at a clinically stable baseline. The mean CAT score for the TRIBE 
cohort was 19.3 (7.8) and mean SGRQ was 42.0 (19.7). There was a strong correlation between CAT and 
SGRQ in TRIBE (r=0.90, p<0.0001) (figure 1). The mean CAT score for the validation cohort was 21.2 (7.8) 
and the mean SGRQ score was 52.7 (20.4) (r=0.87, p<0.0001). The CAT score also correlated well with 
each of the domains within SGRQ:  SGRQ Symptoms r=0.68,
 
p<0.0001, SGRQ Activity r=0.84, p<0.0001, 
SGRQ Impacts (psycho-social) r=0.83, p<0.0001 (figure S1 online). 
 
Convergent validity - QOL-B and LCQ 
QOL-B data were only available for validation cohort and LCQ data were only available in the TRIBE 
cohort.  There was a clear inverse relationship between CAT and QOL-B Respiratory Symptoms Scale 
(QOL-B-RSS) (r=-0.75, p<0.0001) and LCQ total score (r=-0.77, p<0.0001), noting that lower scores on 
both scales indicate worse symptoms (figure 2).  The CAT was also associated with the individual 
components of the LCQ score (figure S2 online). 
 
Convergent validity - other bronchiectasis severity markers 
CAT scores were compared to clinical assessments used to assess bronchiectasis severity. BSI score and 
FEV1 % predicted were available for both cohorts, 6MWD was available for TRIBE cohort only. 
Exacerbation frequency was available in both cohorts, but the TRIBE cohort was not evaluated as it was 
recruited on the basis of exacerbation history at baseline. The mean 6MWD in TRIBE was 420 metres. 
There was a clear relationship between 6MWD and CAT score (r=0.58, p<0.0001) (figure 3). Patients 
with more frequent exacerbations in the validation cohort had higher CAT score (p=0.0054 comparing 
across groups using ANOVA).  Mean BSI in TRIBE cohort was 6.6 (3.2), and there was a significant 
correlation between BSI and CAT (r=0.34,
 
p=0.017). The mean BSI in validation cohort was 9.4 (4.1) with 
a significant relationship also evident in this cohort by linear regression (r=0.63, p<0.001). A weak 
relationship between CAT and FEV1 % predicted was observed in the TRIBE cohort (r=-0.34, p=0.02), 
which was not replicated in the validation cohort (r=-0.20, p=0.3). 
 
Change in CAT at acute exacerbation and after treatment 
Data were available for 24 patients experiencing exacerbations during TRIBE study. The CAT was 
completed at start of treatment and following a two-week course of antibiotics. The mean change in 
CAT from stable baseline was 3.57 (95% CI 0.75 to 6.4, p=0.01) at the onset of an exacerbation indicating 
a statistically significant increase in CAT score. Interestingly, some patients showed no change or 
minimal change in the CAT score at exacerbation. A statistically significant change was also observed 
following antibiotic treatment with a mean change from exacerbation onset to completion of treatment 
of -4.83 (95% CI -1.5 to -6.5, p=0.003). Figure 4A shows the dynamics of CAT scores in individual subjects 
at the onset of exacerbation and following antibiotic treatment. Figure 4B shows the mean and standard 
deviation of the group changes.  
 
Repeatability and calculation of minimum clinically important difference 
Test-retest repeatability was only evaluated in the TRIBE cohort in the same 24 patients described 
above. The intraclass correlation coefficient for two measurements of the CAT score in individuals four 
weeks apart without changes in clinical status was 0.88 (95% CI 0.73 to 0.95, p<0.0001) indicating a high 
degree of repeatability and reliability. The Bland-Altman plot is shown in figure S3 online.  
During recovery from exacerbation over an eight-week period patients experienced improvements in 
the CAT, SGRQ and LCQ in the TRIBE study. As no difference was observed between those patients 
randomized to pulmonary rehabilitation or standard care in the original trial, the data were pooled for 
calculation of the MCID.  
The change in CAT correlated with a change in SGRQ (r=0.68, p=0.0004) and the LCQ (r=-0.57, p=0.004). 
For calculation of the MCID we used a ½ standard deviation as a distribution based method and the 
multiple anchor-based methods. The distribution-based methods suggested an MCID of 3-4. The anchor-
based methods similarly suggested an MCID between 3 and 4 (table 1). Based on these data the most 
reliable MCID was proposed to be 4 points. 
 
 
Discussion  
 
Based on these data, we have shown that the CAT is a valid tool to measure symptoms and treatment 
responses in patients with bronchiectasis. This tool is simple, easy to administer and consists of only 
eight items, allowing patients to complete it in a few minutes.
22,23
 The CAT measures the severity of 
respiratory symptoms that are common to all airways diseases including bronchiectasis and COPD. The 
name “Chronic Airways Assessment Test” rather than “COPD Assessment Test” may be more 
appropriate in view of its broader applicability to several respiratory conditions. The CAT has been 
shown to appropriately indicate symptoms similarly during pulmonary rehabilitation in both COPD 
patients and non-COPD ptients in a prospective study of 365 patients in the UK, while the CAT has also 
been found to have prognostic value in interstitial lung disease.
29,30
  
 
Our study builds on prior studies that have evaluated different aspects of the CAT in bronchiectasis 
patients.
25,31
 Lanza et al investigated 100 patients from Brazil in a cross-sectional study and found strong 
relationships between CAT and disease severity, SGRQ and exercise capacity.
25
 Brill et al studied 22 
patients with bronchiectasis and found a significant increase in CAT scores as part of a study to evaluate 
the dynamics of symptoms around exacerbations.
31
 Neither study was specifically designed to validate 
the CAT using assessment of convergent validity, responsiveness, repeatibility nor calculation of the 
minimum clinically important difference. 
 
In our study, the CAT score consistently correlated to the multiple questionnaires including the SGRQ, 
QOL-B and LCQ. The strenght of this correlation suggests that all are measuring similar aspects of the 
disease with the advantage of the CAT being its greater simplicity and ease of administration. The CAT 
also correlated well to exacerbation frequency in the cross-sectional validation cohort as well as lung 
function and 6MWD. Overall, this suggests that the CAT test is a valid tool and provides an immediate 
assessment of the severity of disease and the degree of disability.  
 
The benefits of using a questionnaire such as the CAT are that it is simpler and faster to administer and 
can easily be performed in the outpatient setting during consultations or in the waiting room. The 
questions are clear and easy for patients to understand. Its design makes it more likely to be accepted 
by patients than the more complex questionnaires with multiple sections.
23,24
  The CAT is also available 
as an online tool that patients can perform independently and has been validated in 90 languages for 
COPD.  
 
We have demonstrated that the CAT questionnaire indicates a worsening of symptoms at the onset of 
an exacerbation and improvement following recovery from an exacerbation. Changes in the CAT 
correlate to changes in the SGRQ and LCQ, all of which suggest that the CAT should be responsive to 
interventions that have a beneficial effect on symptoms. We were interested to observe that the CAT 
score did not always increase from the baseline value to the onset of exacerbation. We observed that 
patients symptoms fluctuated over time and this was also observed in the repeatibility analysis where 
most patients CAT scores were stable but some showed up to a 10 point change due to day to day 
variability in the absence of an exacerbation. A subject could therefore potentially, for example, have a 
CAT score of 10 at baseline, 2 at a subsequent visit and then a score of 11 at exacerbation. The change 
from baseline would be minimal but the change from their other more recent symptoms might be large. 
Variability in day to day symptoms is a phenomenon that has been observed in COPD and other 
respiratory diseases and is likely to be identified in broncheictasis. Studies using electronic or other 
diaries may be more sensitive and useful to evaluate the dynamics of symptom changes around 
exacerbation.  
 
Identifying better ways of capturing symptomatic treatment benefits is a key research priority in 
bronchiectasis at present.32 Multiple clinical trials assessing different medications  have failed to 
demonstrate consistent symptom benefits.33 Possible explanations for this include that inhaled 
antibiotics are not effective at reducing symptoms or that the current symptom tools are poorly adapted 
to measuring treatment responses in bronchiectasis patients. In the recent inhaled antibiotic studies, 
the disease specific QOL-B tool failed to change in response to liposomal ciprofloxacin treatment in the 
ORBIT studies despite an exacerbation benefit in the pooled analysis.33 The SGRQ responded in RESPIRE 
1, particularly in the 14-day on/off arm, but the QOL-B showed no similar benefits. Likewise, the QOL-B 
did not show clear benefits in the AIR-BX studies of aztreonam, although we have recently postulated 
that this may have been due to inclusion of patients with low bacterial load.
34
 The SGRQ has shown a 
degree of responsiveness in studies of macrolides and mannitol.
35
 Therefore to date, the SGRQ has been 
the most responsive tool in this disease, but is limited by complexity. The CAT is therefore attractive 
because of its close correlation with the SGRQ. Prospective testing of the CAT in clinical trials is, 
however, needed.  
 
We have proposed a minimum clinically important difference of 4 points based on the changes observed 
in this study. There is no single accepted method of determining the MCID and so we used multiple 
methods. The methods used suggested an MCID between 3 and 5 would be considered approrpirate. It 
should be noted that the MCID proposed for COPD is 2 points.
23
 In their study evaluating the CAT in 
>700 patients with COPD across two cohorts, Kon et al found distribution based analysis suggested an 
MCID of 3 to 4 points, but the linear regression suggested MCIDs through correlation with the SGRQ 
score of 2 or 3 points and selected 2 points based on receiver operator characteristic curve analysis.
23
 
The findings of their analysis are therefore very similar to ours even if the conclusion regarding the MCID 
is modestly different. The different relationship between CAT and SGRQ in the two studies may 
represent genuine differences in treatment response between bronchiectasis and COPD or our smaller 
sample size.  Our repeatibility analysis in particular was limited by a small sample. Our findings with 
regard to MCID should be considered preliminary as future studies with larger numbers of patients 
testing different clinical interventions may identify different patterns of response. Patients with 
bronchiectasis are heterogeneous and so validation in different patient cohorts would be valuable. In 
paralel with our study another validation study of the CAT in bronchiectasis has recently been 
conducted in Spain. This study by De La Rosa Carillo found that the CAT had excellent internal 
consistency and repeatibility and correlated well with other questionnaires include the bronchiectasis 
health questionnaire and SGRQ and QOL-B.
36
 The authors proposed an MCID of 3 points based on two 
measures of distribution of the change in CAT score around exacerbation. Our study included 131 
patients in total from the UK while the De La Rosa Carillo study included 96 patients from Spain. The two 
studies used a different design and different methods of analysis and therefore provide complementary 
information on the utility of the CAT in bronchiectasis.
36
 
 
Our study is limited by the questionnaires being administered in English and only with patients included 
in the UK. Nevertheless the characteristics of our patients are broadly representative of those in larger 
bronchiectasis patient populations across Europe. We included two patient cohorts in our study with the 
objective of providing a higher degree of confidence in our findings through cross-validation. 
Bronchiectasis is a rapidly changing field and this is reflected in our data, where the QOL-B was only 
available in one study cohort because it was not developed or validated when the TRIBE study was 
initiated. Neither study evaluated the Bronchiectasis Health Questionnaire, a shorter disease specific 
QOL tool similar in design to the CAT, which is awaiting further validation.
2,9
 
 
Future studies could focus on assessing the utility of the CAT in a larger bronchiectasis population across 
multiple centres with a longer period of follow up, and incorporation into clinical trials to assess how it 
responds to therapy and correlates to longer-term morbidity, mortality and disease progression.  
 
Conclusion 
 
This study has validated the CAT questionnaire for use in patients with bronchiectasis. We suggest an 
MCID of 4 points when used for bronchiectasis. We demonstrate that the CAT is a potentially useful tool 
for assessing symptoms and QOL in patients with bronchiectasis in clinical practice and in future clinical 
trials.  
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Definition Result (SD or mean 
change in CAT) 
Proposed MCID 
Distribution based 
½ SD TRIBE cohort 
½ SD validation cohort 
Anchor based 
Exacerbation onset 
Exacerbation recovery 
4 point change in SGRQ as anchor 
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3.43 
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Table 1. Minimum clinically important differences of the CAT in bronchiectasis 
 
 
 
Figure legends 
Figure 1. Comparison of CAT score and SGRQ total score in the TRIBE and validation cohorts. 
 
Figure 2. Comparison of CAT score and QOL-B in validation cohort and the CAT and LCQ in the TRIBE 
cohort. 
 
Figure 3. Convergent validity of the CAT score with BSI, 6MWD and exacerbation frequency. 
 
Figure 4. Change in CAT score at the onset and then recovery from exacerbation. A: Change over time 
from stable state to exacerbation and then post-treatment (14 days after antibiotic treatment). B: mean 
and standard deviation differences between stable state and exacerbation and then exacerbation onset 
and recovery, representing clinically meaningful changes in patient status. 
 
 
 
 
 
 
 
1.3 point change in LCQ as anchor 3.78 4 
 




